PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Identifies how quickly the company is scaling its balance sheet (via acquisitions, expansions, or debt). Strong growth, accompanied by sound fundamentals, can support long-term intrinsic value—while disproportionate debt expansion or bloated intangible assets can signal elevated risk.
-5.12%
Both companies show declining cash positions (-5.12% vs AXSM's -24.56%). Seth Klarman would examine if this reflects broader market conditions or operational challenges.
No Data
No Data available this quarter, please select a different quarter.
-5.12%
Below half of AXSM's -24.56%. Michael Burry might suspect a liquidity shortfall if there's no alternative capital plan.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
820.83%
Higher Other Current Assets Growth compared to AXSM's zero value, indicating worse performance.
-4.22%
Below half of AXSM's -24.78%. Michael Burry could suspect a liquidity squeeze. Verify operational performance.
-17.65%
0.5-0.75x AXSM's -24.56%. Martin Whitman might see a risk of falling behind in asset investment or shifting strategy.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-100.00%
Both AXSM and the company show zero Long-Term Investments Growth.
No Data
No Data available this quarter, please select a different quarter.
-100.00%
Higher Other Non-Current Assets Growth compared to AXSM's zero value, indicating worse performance.
-47.54%
≥ 1.5x AXSM's -19.53%. David Dodd sees significantly higher long-term asset buildup. Confirm synergy with strategy.
No Data
No Data available this quarter, please select a different quarter.
-4.84%
Below half of AXSM's -390.19%. Michael Burry sees a potential red flag for stagnation or capital shortage.
46.70%
Less than half of AXSM's -1.74%. David Dodd sees a more disciplined AP approach or lower volume.
-26.38%
Higher Short-Term Debt Growth compared to AXSM's zero value, indicating worse performance.
No Data
No Data available this quarter, please select a different quarter.
126.45%
Higher Deferred Revenue (Current) Growth compared to AXSM's zero value, indicating better performance.
265.71%
Higher Other Current Liabilities Growth compared to AXSM's zero value, indicating worse performance.
63.25%
Less than half of AXSM's -6.65%. David Dodd sees a more disciplined short-term liability approach.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-25.00%
Above 1.5x AXSM's -0.17%. Michael Burry sees a strong spike vs. competitor. Check coverage and debt ratios.
No Data
No Data available this quarter, please select a different quarter.
63.16%
Less than half of AXSM's -4.11%. David Dodd sees far fewer liability expansions relative to competitor.
No Data
No Data available this quarter, please select a different quarter.
-3.23%
Below half AXSM's -9.05%. Michael Burry suspects major net losses or high dividends vs. competitor.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-8.40%
Below half AXSM's -1057.91%. Michael Burry sees potential underperformance in building shareholder capital.
-4.84%
Below half AXSM's -390.19%. Michael Burry sees significant shrinkage or inactivity vs. competitor.
-100.00%
Both AXSM and the company show zero Total Investments Growth.
-26.37%
Above 1.5x AXSM's -0.69%. Michael Burry sees a major jump. Investigate leverage rationale.
5.01%
Less than half of AXSM's 43.06%. David Dodd sees better deleveraging or stronger cash buildup than competitor.